Relationship between the Coronary Slow Flow Phenomenon and the Vertebrobasilar Insufficiency

Yasin Yüksel 1, Cennet Yildiz 2 * , İbrahim Taşkın Rakici 3, Cansu Erkol 4, Fatma Nihan Turhan Çağlar 2
More Detail
1 Cardiology Department, Private Kolan Hospital, Istanbul, Turkey
2 Cardiology Department, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
3 Radiology Department, Istanbul Training and Research Hospital, Istanbul, Turkey.
4 Neurology Department, Istanbul Training and Research Hospital, Istanbul, Turkey
* Corresponding Author
J CLIN MED KAZ, In press. https://doi.org/10.23950/jcmk/15866
OPEN ACCESS 104 Views 0 Downloads

ABSTRACT

Background: Coronary slow flow phenomenon (CSFP) and vertebrobasilar insufficiency (VBI) may have common pathophysiological mechanism.
Aim: Our aim was to investigate whether there is an association between vertebrobasilar flow assessed by Doppler sonography and CSFP assessed by Thrombolysis in Myocardial Infarction (TIMI) frame count.
Methods: We included 241 patients who had CSFP and underwent vertebrobasilar Doppler sonography. Patients with vertebral artery blood flow volumes greater than 200 ml/min and equal to or less than 200 ml/min were classified into the normal flow and low flow groups, respectively. Hospital records were used to determine the biochemical and demographic characteristics of the patients.
Results: The mean age of the study population was 58.75±9.34 years. We found no differences between patients with normal and low vertebral blood flow in terms of age, sex, body mass index, smoking habit, presence of hypertension, hyperlipidemia, diabetes mellitus or medication use. Patients with low vertebral blood flow were found to have greater mean platelet volume. The mean TIMI frame count and LAD, Cx, and RCA TIMI frame counts were significantly greater in patients with low vertebral blood flow and were negatively correlated with the vertebral artery blood flow volume (p<0.001 for all). A mean TIMI frame count of 24.5 predicted VBI, with a sensitivity and specificity of 61.2% and 86.8%, respectively. The only predictor of VBI was the mean TIMI frame count (OR: 1.066, 95% confidence interval: 1.043–1.091, P<0.001).
Conclusion: Our findings suggest that a common pathophysiological mechanism may underlie both CSFP and VBI.
Keywords: Coronary, slow flow, vertebrobasilar, flow.

CITATION

Yüksel Y, Yildiz C, Rakici İT, Erkol C, Çağlar FNT. Relationship between the Coronary Slow Flow Phenomenon and the Vertebrobasilar Insufficiency. J Clin Med Kaz. 2025. https://doi.org/10.23950/jcmk/15866

REFERENCES

  • Neto ACL, Bittar R, Gattas GS, Bor-Seng-Shu E, Oliverira ML, Monsanto RC, et al. Pathophysiology and Diagnosis of Vertebrobasilar Insufficiency: A Review of the Literature. Int Arch Otorhinolaryngol. 2017; 21(3): 302–307. https://doi.org/10.1055/s-0036-1593448.
  • Pirau L, Lui F. Vertebrobasilar Insufficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024.
  • Strek P, Reron E, Maga P, Modrzejewski M, Szybist N. A possible correlation between vertebral artery insufficiency and degenerative changes in the cervical spine. Eur Arch Otorhinolaryngol. 1998; 255:437–340. https://doi.org/10.1007/s004050050094.
  • Alvarez C, Siu H. Coronary slow-flow phenomenon as an underrecognized and treatable source of chest pain: case series and literature review. J Investig Med High Impact Case Rep. 2018; 6:1–5. Https://doi.org/10.1177/2324709618789194
  • Chalikias G, Tziakas D. Slow Coronary Flow: Pathophysiology, Clinical Implications, and Therapeutic Management. Angiology. 2021; 72(9): 808–818. https://doi.org/10.1177/00033197211004390.
  • Zhu Q, Wang S, Huang X, Zhao C, Wang Y, Li X, Jia D, Ma C. Understanding the pathogenesis of coronary slow flow: Recent advances. Trends Cardiovasc Med. 2024; 34(3): 137–144. https://doi.org/10.1016/j.tcm.2022.12.001.
  • Caiati C, Lacovelli F, Mancini G, Lepera ME. Hidden Coronary Atherosclerosis Assessment but Not Coronary Flow Reserve Helps to Explain the Slow Coronary Flow Phenomenon in Patients with Angiographically Normal Coronary Arteries. Diagnostics (Basel). 2022; 12(9): 2173. https://doi.org/10.3390/diagnostics12092173.
  • Kern MJ, Moore JA, Aguirre FV, Bach RG, Caracciolo EA, Wolford T, Khoury AF, Mechem C, Donohue TJ. Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarction. Circulation. 1996; 94(7): 1545–1552. https://doi.org/10.1161/01.cir.94.7.1545.
  • Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: aquantitative method of assessing coronary artery flow. Circulation. 1996; 93: 879–888. https://doi.org/10.1161/01.cir.93.5.879.
  • Savits SI, Caplan LR. Vertebrobasilar disease. N Engl J Med. 2005; 352(25): 2618-2626. https://doi.org/10.1056/NEJMra041544.
  • Gulli G, Khan S, Markus HS. Vertebrobasilar stenosis predicts high early recurrent stroke risk in posterior circulation stroke and TIA. Stroke. 2009; 40 (8): 2732–2737. https://doi.org/10.1161/STROKEAHA.109.553859.
  • Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke. 1998; 29(7): 1389–1392. https://doi.org/10.1161/01.str.29.7.1389.
  • Qureshi AI, Suri MFK, Ziai WC, Yahia AM, Mohammad Y, Sen S, Agarwal P, Zaidat OO, Suarez JI, Wityk RJ. Stroke-free survival and its determinants in patients with symptomatic vertebrobasilar stenosis: a multicenter study. Neurosurgery. 2003; 52(5): 1033–1040. https://doi.org/10.1227/01.NEU.0000057744.96295.9F.
  • Doss A, Phatouros CC. Vertebrobasilar insufficiency. Curr Treat Options Cardio Med. 2006; 8: 111–119. https://doi.org/10.1007/s11936-006-0003-0.
  • Zhang Q, Liu J, Duan H, Li R, Peng W, Wu C. Activation of Nrf2/HO-1 signaling: an important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res. 2021; 34: 43–63. https://doi.org/10.1016/j.jare.2021.06.023.
  • Camsarl A, Pekdemir H, Cicek D, Polat G, Akkus MN, Doven O, et al.Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J. 2003; 67: 1022–1028. https://doi.org/10.1253/circj.67.1022.
  • Fleming I, Bauersachs J, Busse R. Paracrine functions of the coronary vascular endothelium. Mol Cell Biochem. 1996; 157: 137–145. https://doi.org/10.1007/BF00227892.
  • Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, Ritter JK. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci. 2018; 19(9): 2605. https://doi.org/10.3390/ijms19092605.
  • Beltrame JF, Cutri N, Kopetz V, Tavella R. The role of nitric oxide in the coronary slow flow phenomenon. Coron Artery Dis. 2014; 25: 187–189. https://doi.org/10.1097/MCA.0000000000000112.
  • Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, Karakaya O. Plasma nitric oxide level and its role in slow coronary flow phenomenon. Int Heart J. 2005; 46(3): 373–382. https://doi.org/10.1536/ihj.46.373.
  • Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology. 2012; 121: 197–203. https://doi.org/10.1159/000336948.
  • Kayapinar O, Ozde C, Kaya A. Relationship between the reciprocal change in inflammation-related biomarkers (Fibrinogen-to-albumin and hsCRP-to-albumin ratios) and the presence and severity of coronary slow flow. Clin Appl Thromb Hemost. 2019; 25: 1076029619835383. https://doi.org/10.1177/1076029619835383.
  • Li JJ, Qin XW, Li ZC, Zeng HS, Gao Z, Xu B, Zhang CY, Li J. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta. 2007; 385: 43–47. https://doi.org/10.1016/j.cca.2007.05.024.
  • Turhan H, Saydam GS, Erbay AR, Ayaz S, Yasar AS, Aksoy Y, Basarc N, Yetkin E. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2006; 108: 224–230. https://doi.org/10.1016/j.ijcard.2005.05.008.
  • Gökçe M, Kaplan S, Tekelioğlu Y, Erdoğan T, Küçükosmanoğlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol. 2005; 28: 145–148. https://doi.org/10.1002/clc.4960280310.
  • Cetin MS, Ozcan Cetin EH, Canpolat U, Aydın S, Temizhan A, Topaloglu S, Aras D, Aydogdu S. An overlooked parameter in coronary slow flow phenomenon: whole blood viscosity. Biomark Med. 2015; 9: 1311–1321. https://doi.org/10.2217/bmm.15.92.
  • Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003; 146: 84–90. https://doi.org/10.1016/S0002-8703(03)00124-8.
  • Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986; 74: 964–972. https://doi.org/10.1161/01.cir.74.5.964.
  • Fineschi M, Bravi A, Gori T. The “slow coronary flow” phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistances. Int J Cardiol. 2008; 127: 358–361. https://doi.org/10.1016/j.ijcard.2007.06.010.
  • Cin VG, Pekdemir H, Camsar A, Ciçek D, Akkus MN, Parmaksız T, Katýrcýbaºý T, Döven O. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J. 2003; 44: 907–919. https://doi.org/10.1536/jhj.44.907.
  • Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Döven O, Parmaksiz HT. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol. 2004; 59: 127–133. https://pubmed.ncbi.nlm.nih.gov/15139652/. https://doi.org/10.2143/AC.59.2.2005166.
  • Acar M, Degirmenci B, Yucel A, Albayrak R, Haktanır A, Yaman M. Comparison of vertebral artery velocity and flow volume measurements for diagnosis of vertebrobasilar insufficiency using color duplex sonography. Eur J Radiol. 2005; 54(2): 221–224. https://doi.org/10.1016/j.ejrad.2004.06.017.